CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

COVID-19: An Update From Dr. Brian O’Rourke, CADTH President and CEO

March 18, 2020
For the latest updates and guidance on COVID-19, please consult the Public Health Agency of Canada. As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the risks to our staff and ensure that we continue to support Canada’s health care decision-makers during this period. Public health authorit...

Drug Reimbursement Recommendation - tafamidis (Vyndaqel)

February 21, 2020
Today, CADTH has issued final recommendations for: tafamidis (Vyndaqel) Indications: transthyretin-mediated amyloidosis Recommendation: Reimburse with clinical criteria and/or conditions For more information

Call for Feedback: Rituximab to Treat Primary Membranous Nephropathy

February 13, 2020
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders. Rituximab to Treat Primary Membranous Nephropathy Call for Feedback: 2020-02-13 Feedback Due By: 2020-02-28 Consultation Document: Proposed Project Scope Product Type: Health Technology Assessment Submit Feedback

New at CADTH — February 2020

February 10, 2020
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.